`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Case IPR2017-01053
`Patent 8,268,299
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioner
`
`v.
`
`ALCON RESEARCH, LTD.,
`Patent Owner
`
`
`Case IPR2017-01053
`Patent 8,268,299
`
`
`ALCON RESEARCH, LTD.’S MOTION TO UNSEAL AND MOTION FOR
`ENTRY OF THE DEFAULT STANDING PROTECTIVE ORDER
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2017-01053
`
`Patent 8,268,299
`
`Pursuant to 37 C.F.R. § 42.54, and in response to the Board’s January 19,
`
`2018 Order Denying Without Prejudice Patent Owner’s Motion to Seal and for
`
`Entry of Proposed Protective Order, Patent Owner Alcon Research, Ltd. (“Alcon”)
`
`hereby respectfully moves:
`
` to unseal Exhibits 2008–2022, 2029, and 2040–58;
`
` for entry of the Default Standing Protective Order (Exhibit 2140).
`
`Proposed Protective Order
`
`A.
`Pursuant to 37 C.F.R. § 42.54, Alcon is moving again for entry of the
`
`Default Standing Protective Order. See Ex. 2140. Alcon has produced to
`
`Petitioner Argentum Pharmaceuticals LLC (“Argentum”) raw data owned by each
`
`of IMS Health/IQVIA and Encuity Research. Alcon’s contracts with these
`
`companies require it to only disclose these data to third parties (such as Argentum)
`
`pursuant to a protective order. In addition, Alcon has produced the complete
`
`versions of the lab notebooks and adjunctive data that are excerpted in Exhibits
`
`2008–2022, each of which contains Alcon’s confidential information that is not
`
`relevant to this case and has never been publicly disclosed. These materials have
`
`not been filed. Alcon requests that the default protective order be entered so that it
`
`continues to govern the treatment of confidential information exchanged among
`
`the parties. See Ex. 2140 ¶ 4(B).
`
`
`
`1
`
`
`
`
`
`
`Case IPR2017-01053
`
`Patent 8,268,299
`
`B. Certification of Conference with Opposing Party Pursuant to 37
`C.F.R. § 42.54
`
`Alcon certifies that Argentum consents to Alcon’s Motion for Entry of the
`
`Default Standing Protective Order and will not be filing an opposition.
`
`
`
`Dated: January 25, 2018
`
`Respectfully submitted,
`
`/David M. Krinsky/
`David M. Krinsky
`Reg. No. 72,339
`Lead Counsel for
`Patent Owner
`
`Williams & Connolly LLP
`725 Twelfth Street NW
`Washington, D.C. 20005
`202-434-5338 (Telephone)
`202-434-5029 (Facsimile)
`dkrinsky@wc.com
`
`
`
`
`
`2
`
`
`
`
`
`
`Case IPR2017-01053
`
`Patent 8,268,299
`
`CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))
`
`The undersigned hereby certifies that the foregoing “ALCON RESEARCH,
`
`LTD.’S MOTION TO UNSEAL AND MOTION FOR ENTRY OF THE
`
`DEFAULT STANDING PROTECTIVE ORDER” was served on January 25,
`
`2018, via electronic mail upon the following attorneys of record for the Petitioner:
`
`Michael R. Houston
`Joseph P. Meara
`James P. McParland
`FOLEY & LARDNER LLP
`mhouston@foley.com
`jmeara-pgp@foley.com
`jmcparland@foley.com
`ARG-travatanZ@foley.com
`
`Tyler C. Liu
`ARGENTUM PHARMACEUTICALS LLC
`tliu@agpharm.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/David M. Krinsky/
`David M. Krinsky
`Reg. No. 72,339
`Lead Counsel for Patent Owner
`
`
`
`
`
`Dated: January 25, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`